Regulatory patterns of Chinese patent medicine for lipid metabolism disorders in patients with type 2 diabetes mellitus complicated by ischemic stroke: A systematic review and network meta-analysis
To investigate the regulatory patterns of Chinese patent medicine (CPM) interventions on lipid metabolism disorders in patients with type 2 diabetes mellitus (T2DM) complicated by ischemic stroke. Two researchers independently searched 8 major databases and created a comprehensive database containin...
Gespeichert in:
| Veröffentlicht in: | Medicine (Baltimore) 2024-05, Vol.103 (20), p.e35050-e35050 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e35050 |
|---|---|
| container_issue | 20 |
| container_start_page | e35050 |
| container_title | Medicine (Baltimore) |
| container_volume | 103 |
| creator | Lu, Zhenkai Zhang, Xuming Xie, Yanming |
| description | To investigate the regulatory patterns of Chinese patent medicine (CPM) interventions on lipid metabolism disorders in patients with type 2 diabetes mellitus (T2DM) complicated by ischemic stroke.
Two researchers independently searched 8 major databases and created a comprehensive database containing all randomized controlled trials (RCTs) that investigated the application of "blood-activating and stasis-removing" CPM in the treatment of stroke combined with T2DM until October 1, 2022. The collected data were compiled and organized in Excel. Quality assessment was performed using the Cochrane 5.3 bias risk assessment tool, and the network meta-analysis was conducted using R software.
A total of 12 articles were included in the final analysis, covering 4 types of CPM: Naoxintong Capsules (NXT), Tongmai Jiangtang Capsules, Tongxinluo Capsules (TXL), and Yindan Xinnaotong Soft Capsules. Among these, CPM formulations containing herbs with blood-activating and stasis-removing properties were the most commonly used. The results of the network meta-analysis are as follows: (1) the combination of 3 CPM formulations showed superior efficacy in improving total cholesterol levels compared to conventional Western medicine treatment (CT). In particular, Yindan Xinnaotong Soft Capsules + CT (surface under the cumulative ranking curve [SUCRA] = 97.24%) demonstrated the highest efficacy, followed by NXT + CT (SUCRA = 66.23%), and then TXL + CT (SUCRA = 55.16%). (2) TXL + CT treatment exhibited the most promising efficacy in improving triglyceride levels (P |
| doi_str_mv | 10.1097/MD.0000000000035050 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11098261</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3056662038</sourcerecordid><originalsourceid>FETCH-LOGICAL-c356t-e77998b3f62ab4c3a0aa6e44dbb3460ea6360ba80eff42bbbc257849f38aa7fd3</originalsourceid><addsrcrecordid>eNpdUstu1TAQtRCIXgpfgIRmySatEydOwgZVt7ykVkgI1pbtTHpNkzh4nF7lA_tf-NJSHrMZ6ficM54HYy9zfpLztj69PD_hf0JUvOKP2CavhMyqVpaP2Ybzosrqti6P2DOi75znoi7Kp-xINHXVNFJs2O0XvFoGHX1YYdYxYpgIfA_bnZuQ8IDhFGHEztmEQO8DDG52XYKiNn5wNELnyIcOA4GbDgqXJAR7F3cQ1xmhSAxtMCIl1TC4uBBYP86Ds8m-A7OCI7vD0VmgGPw1voEzoJUijsnNQsAbh3vQUwcTxr0P17_KZ3rSw0qOnrMnvR4IX9znY_bt_buv24_ZxecPn7ZnF5kVlYwZ1nXbNkb0stCmtEJzrSWWZWeMKCVHLYXkRjcc-74sjDG2qOqmbHvRaF33nThmb-9858WkkdjUZ9CDmoMbdViV1079-zK5nbryNypPG2sKmSeH1_cOwf9YkKIaU-tpKHpCv5ASvJJSFlw0iSruqDZ4ooD9Q52cq8MFqMtz9f8FJNWrv7_4oPm9cvET6Taziw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3056662038</pqid></control><display><type>article</type><title>Regulatory patterns of Chinese patent medicine for lipid metabolism disorders in patients with type 2 diabetes mellitus complicated by ischemic stroke: A systematic review and network meta-analysis</title><source>Wolters Kluwer Open Health</source><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>IngentaConnect Free/Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Lu, Zhenkai ; Zhang, Xuming ; Xie, Yanming</creator><creatorcontrib>Lu, Zhenkai ; Zhang, Xuming ; Xie, Yanming</creatorcontrib><description>To investigate the regulatory patterns of Chinese patent medicine (CPM) interventions on lipid metabolism disorders in patients with type 2 diabetes mellitus (T2DM) complicated by ischemic stroke.
Two researchers independently searched 8 major databases and created a comprehensive database containing all randomized controlled trials (RCTs) that investigated the application of "blood-activating and stasis-removing" CPM in the treatment of stroke combined with T2DM until October 1, 2022. The collected data were compiled and organized in Excel. Quality assessment was performed using the Cochrane 5.3 bias risk assessment tool, and the network meta-analysis was conducted using R software.
A total of 12 articles were included in the final analysis, covering 4 types of CPM: Naoxintong Capsules (NXT), Tongmai Jiangtang Capsules, Tongxinluo Capsules (TXL), and Yindan Xinnaotong Soft Capsules. Among these, CPM formulations containing herbs with blood-activating and stasis-removing properties were the most commonly used. The results of the network meta-analysis are as follows: (1) the combination of 3 CPM formulations showed superior efficacy in improving total cholesterol levels compared to conventional Western medicine treatment (CT). In particular, Yindan Xinnaotong Soft Capsules + CT (surface under the cumulative ranking curve [SUCRA] = 97.24%) demonstrated the highest efficacy, followed by NXT + CT (SUCRA = 66.23%), and then TXL + CT (SUCRA = 55.16%). (2) TXL + CT treatment exhibited the most promising efficacy in improving triglyceride levels (P < .05), while the effects of the other 3 CPM formulations were not statistically significant. (3) In terms of improving low-density lipoprotein levels, NXT + CT (SUCRA = 82.27%) showed better efficacy than TXL + CT (SUCRA = 73.99%), while the effects of the other 2 CPM formulations were not statistically significant. (4) The combination of CPM formulations and CT resulted in a lower incidence of adverse reactions compared to CT (P < .05).
The treatment of patients with T2DM complicated by ischemic stroke commonly involved the use of "blood-activating and stasis-removing" herbal medicines. These herbal medicines have shown effectiveness in regulating patients' blood lipid levels. However, it is crucial to acknowledge that the analysis was influenced by variations in the number and quality of RCTs involving different CPM formulations. Therefore, additional validation through large-scale, high-quality RCT studies is required.</description><identifier>ISSN: 0025-7974</identifier><identifier>EISSN: 1536-5964</identifier><identifier>DOI: 10.1097/MD.0000000000035050</identifier><identifier>PMID: 38758863</identifier><language>eng</language><publisher>United States: Lippincott Williams & Wilkins</publisher><subject>Diabetes Mellitus, Type 2 - complications ; Diabetes Mellitus, Type 2 - drug therapy ; Drugs, Chinese Herbal - therapeutic use ; Humans ; Ischemic Stroke - drug therapy ; Lipid Metabolism Disorders - drug therapy ; Lipid Metabolism Disorders - etiology ; Medicine, Chinese Traditional - methods ; Network Meta-Analysis ; Randomized Controlled Trials as Topic ; Systematic Review and Meta-Analysis</subject><ispartof>Medicine (Baltimore), 2024-05, Vol.103 (20), p.e35050-e35050</ispartof><rights>Copyright © 2024 the Author(s). Published by Wolters Kluwer Health, Inc.</rights><rights>Copyright © 2024 the Author(s). Published by Wolters Kluwer Health, Inc. 2024</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c356t-e77998b3f62ab4c3a0aa6e44dbb3460ea6360ba80eff42bbbc257849f38aa7fd3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11098261/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11098261/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38758863$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lu, Zhenkai</creatorcontrib><creatorcontrib>Zhang, Xuming</creatorcontrib><creatorcontrib>Xie, Yanming</creatorcontrib><title>Regulatory patterns of Chinese patent medicine for lipid metabolism disorders in patients with type 2 diabetes mellitus complicated by ischemic stroke: A systematic review and network meta-analysis</title><title>Medicine (Baltimore)</title><addtitle>Medicine (Baltimore)</addtitle><description>To investigate the regulatory patterns of Chinese patent medicine (CPM) interventions on lipid metabolism disorders in patients with type 2 diabetes mellitus (T2DM) complicated by ischemic stroke.
Two researchers independently searched 8 major databases and created a comprehensive database containing all randomized controlled trials (RCTs) that investigated the application of "blood-activating and stasis-removing" CPM in the treatment of stroke combined with T2DM until October 1, 2022. The collected data were compiled and organized in Excel. Quality assessment was performed using the Cochrane 5.3 bias risk assessment tool, and the network meta-analysis was conducted using R software.
A total of 12 articles were included in the final analysis, covering 4 types of CPM: Naoxintong Capsules (NXT), Tongmai Jiangtang Capsules, Tongxinluo Capsules (TXL), and Yindan Xinnaotong Soft Capsules. Among these, CPM formulations containing herbs with blood-activating and stasis-removing properties were the most commonly used. The results of the network meta-analysis are as follows: (1) the combination of 3 CPM formulations showed superior efficacy in improving total cholesterol levels compared to conventional Western medicine treatment (CT). In particular, Yindan Xinnaotong Soft Capsules + CT (surface under the cumulative ranking curve [SUCRA] = 97.24%) demonstrated the highest efficacy, followed by NXT + CT (SUCRA = 66.23%), and then TXL + CT (SUCRA = 55.16%). (2) TXL + CT treatment exhibited the most promising efficacy in improving triglyceride levels (P < .05), while the effects of the other 3 CPM formulations were not statistically significant. (3) In terms of improving low-density lipoprotein levels, NXT + CT (SUCRA = 82.27%) showed better efficacy than TXL + CT (SUCRA = 73.99%), while the effects of the other 2 CPM formulations were not statistically significant. (4) The combination of CPM formulations and CT resulted in a lower incidence of adverse reactions compared to CT (P < .05).
The treatment of patients with T2DM complicated by ischemic stroke commonly involved the use of "blood-activating and stasis-removing" herbal medicines. These herbal medicines have shown effectiveness in regulating patients' blood lipid levels. However, it is crucial to acknowledge that the analysis was influenced by variations in the number and quality of RCTs involving different CPM formulations. Therefore, additional validation through large-scale, high-quality RCT studies is required.</description><subject>Diabetes Mellitus, Type 2 - complications</subject><subject>Diabetes Mellitus, Type 2 - drug therapy</subject><subject>Drugs, Chinese Herbal - therapeutic use</subject><subject>Humans</subject><subject>Ischemic Stroke - drug therapy</subject><subject>Lipid Metabolism Disorders - drug therapy</subject><subject>Lipid Metabolism Disorders - etiology</subject><subject>Medicine, Chinese Traditional - methods</subject><subject>Network Meta-Analysis</subject><subject>Randomized Controlled Trials as Topic</subject><subject>Systematic Review and Meta-Analysis</subject><issn>0025-7974</issn><issn>1536-5964</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdUstu1TAQtRCIXgpfgIRmySatEydOwgZVt7ykVkgI1pbtTHpNkzh4nF7lA_tf-NJSHrMZ6ficM54HYy9zfpLztj69PD_hf0JUvOKP2CavhMyqVpaP2Ybzosrqti6P2DOi75znoi7Kp-xINHXVNFJs2O0XvFoGHX1YYdYxYpgIfA_bnZuQ8IDhFGHEztmEQO8DDG52XYKiNn5wNELnyIcOA4GbDgqXJAR7F3cQ1xmhSAxtMCIl1TC4uBBYP86Ds8m-A7OCI7vD0VmgGPw1voEzoJUijsnNQsAbh3vQUwcTxr0P17_KZ3rSw0qOnrMnvR4IX9znY_bt_buv24_ZxecPn7ZnF5kVlYwZ1nXbNkb0stCmtEJzrSWWZWeMKCVHLYXkRjcc-74sjDG2qOqmbHvRaF33nThmb-9858WkkdjUZ9CDmoMbdViV1079-zK5nbryNypPG2sKmSeH1_cOwf9YkKIaU-tpKHpCv5ASvJJSFlw0iSruqDZ4ooD9Q52cq8MFqMtz9f8FJNWrv7_4oPm9cvET6Taziw</recordid><startdate>20240517</startdate><enddate>20240517</enddate><creator>Lu, Zhenkai</creator><creator>Zhang, Xuming</creator><creator>Xie, Yanming</creator><general>Lippincott Williams & Wilkins</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20240517</creationdate><title>Regulatory patterns of Chinese patent medicine for lipid metabolism disorders in patients with type 2 diabetes mellitus complicated by ischemic stroke: A systematic review and network meta-analysis</title><author>Lu, Zhenkai ; Zhang, Xuming ; Xie, Yanming</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c356t-e77998b3f62ab4c3a0aa6e44dbb3460ea6360ba80eff42bbbc257849f38aa7fd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Diabetes Mellitus, Type 2 - complications</topic><topic>Diabetes Mellitus, Type 2 - drug therapy</topic><topic>Drugs, Chinese Herbal - therapeutic use</topic><topic>Humans</topic><topic>Ischemic Stroke - drug therapy</topic><topic>Lipid Metabolism Disorders - drug therapy</topic><topic>Lipid Metabolism Disorders - etiology</topic><topic>Medicine, Chinese Traditional - methods</topic><topic>Network Meta-Analysis</topic><topic>Randomized Controlled Trials as Topic</topic><topic>Systematic Review and Meta-Analysis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lu, Zhenkai</creatorcontrib><creatorcontrib>Zhang, Xuming</creatorcontrib><creatorcontrib>Xie, Yanming</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Medicine (Baltimore)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lu, Zhenkai</au><au>Zhang, Xuming</au><au>Xie, Yanming</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Regulatory patterns of Chinese patent medicine for lipid metabolism disorders in patients with type 2 diabetes mellitus complicated by ischemic stroke: A systematic review and network meta-analysis</atitle><jtitle>Medicine (Baltimore)</jtitle><addtitle>Medicine (Baltimore)</addtitle><date>2024-05-17</date><risdate>2024</risdate><volume>103</volume><issue>20</issue><spage>e35050</spage><epage>e35050</epage><pages>e35050-e35050</pages><issn>0025-7974</issn><eissn>1536-5964</eissn><abstract>To investigate the regulatory patterns of Chinese patent medicine (CPM) interventions on lipid metabolism disorders in patients with type 2 diabetes mellitus (T2DM) complicated by ischemic stroke.
Two researchers independently searched 8 major databases and created a comprehensive database containing all randomized controlled trials (RCTs) that investigated the application of "blood-activating and stasis-removing" CPM in the treatment of stroke combined with T2DM until October 1, 2022. The collected data were compiled and organized in Excel. Quality assessment was performed using the Cochrane 5.3 bias risk assessment tool, and the network meta-analysis was conducted using R software.
A total of 12 articles were included in the final analysis, covering 4 types of CPM: Naoxintong Capsules (NXT), Tongmai Jiangtang Capsules, Tongxinluo Capsules (TXL), and Yindan Xinnaotong Soft Capsules. Among these, CPM formulations containing herbs with blood-activating and stasis-removing properties were the most commonly used. The results of the network meta-analysis are as follows: (1) the combination of 3 CPM formulations showed superior efficacy in improving total cholesterol levels compared to conventional Western medicine treatment (CT). In particular, Yindan Xinnaotong Soft Capsules + CT (surface under the cumulative ranking curve [SUCRA] = 97.24%) demonstrated the highest efficacy, followed by NXT + CT (SUCRA = 66.23%), and then TXL + CT (SUCRA = 55.16%). (2) TXL + CT treatment exhibited the most promising efficacy in improving triglyceride levels (P < .05), while the effects of the other 3 CPM formulations were not statistically significant. (3) In terms of improving low-density lipoprotein levels, NXT + CT (SUCRA = 82.27%) showed better efficacy than TXL + CT (SUCRA = 73.99%), while the effects of the other 2 CPM formulations were not statistically significant. (4) The combination of CPM formulations and CT resulted in a lower incidence of adverse reactions compared to CT (P < .05).
The treatment of patients with T2DM complicated by ischemic stroke commonly involved the use of "blood-activating and stasis-removing" herbal medicines. These herbal medicines have shown effectiveness in regulating patients' blood lipid levels. However, it is crucial to acknowledge that the analysis was influenced by variations in the number and quality of RCTs involving different CPM formulations. Therefore, additional validation through large-scale, high-quality RCT studies is required.</abstract><cop>United States</cop><pub>Lippincott Williams & Wilkins</pub><pmid>38758863</pmid><doi>10.1097/MD.0000000000035050</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0025-7974 |
| ispartof | Medicine (Baltimore), 2024-05, Vol.103 (20), p.e35050-e35050 |
| issn | 0025-7974 1536-5964 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11098261 |
| source | Wolters Kluwer Open Health; MEDLINE; DOAJ Directory of Open Access Journals; IngentaConnect Free/Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; Alma/SFX Local Collection |
| subjects | Diabetes Mellitus, Type 2 - complications Diabetes Mellitus, Type 2 - drug therapy Drugs, Chinese Herbal - therapeutic use Humans Ischemic Stroke - drug therapy Lipid Metabolism Disorders - drug therapy Lipid Metabolism Disorders - etiology Medicine, Chinese Traditional - methods Network Meta-Analysis Randomized Controlled Trials as Topic Systematic Review and Meta-Analysis |
| title | Regulatory patterns of Chinese patent medicine for lipid metabolism disorders in patients with type 2 diabetes mellitus complicated by ischemic stroke: A systematic review and network meta-analysis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T21%3A51%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Regulatory%20patterns%20of%20Chinese%20patent%20medicine%20for%20lipid%20metabolism%20disorders%20in%20patients%20with%20type%202%20diabetes%20mellitus%20complicated%20by%20ischemic%20stroke:%20A%20systematic%20review%20and%20network%20meta-analysis&rft.jtitle=Medicine%20(Baltimore)&rft.au=Lu,%20Zhenkai&rft.date=2024-05-17&rft.volume=103&rft.issue=20&rft.spage=e35050&rft.epage=e35050&rft.pages=e35050-e35050&rft.issn=0025-7974&rft.eissn=1536-5964&rft_id=info:doi/10.1097/MD.0000000000035050&rft_dat=%3Cproquest_pubme%3E3056662038%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3056662038&rft_id=info:pmid/38758863&rfr_iscdi=true |